Implications for the glucagon receptor component Retatrutide is unique because of its glucagon receptor agonism
In SURPASS-2, which compared tirzepatide to semaglutide (a GLP-1 receptor agonist) in patients taking metformin, tirzepatide 5 mg, 10 mg, and 15 mg doses achieved mean HbA1c reductions of 2.01%, 2.24%, and 2.30% respectively from baseline, compared to 1.86% with semaglutide 1 mg
Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $3.83 per issue Learn more Rent or buy this article Prices vary by article type from$1.95 to$39.95 Learn more Prices may be subject to local taxes which are calculated during checkout Nature 638 , 591-592 (2025) doi: Reprints and permissions Subjects Obesity Drug discovery Latest on: Obesity Drug discovery The latest benefit of obesity drugs: boosting testosterone and sperm quality News Obesity doesnt equate to ill health: why the disease label doesnt always fit Comment A deep-learning framework reveals whole-body perturbations at cell level Article New hope in the fight against cachexia cancers deadly co-conspirator News Feature Could this mysterious disappearing organ hold the key to longevity
[6] Aronne et al
BPC-157 addresses active inflammation and structural tissue injury
What Payers Can Do Now As drug manufacturers ramp up their production of oral GLP-1s, payers must stay ahead of the shift or risk greater utilization and cost pressures
